Drug Trial Radar · NCT04782271
Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops
Last checked: Nov 19, 2026Latest source record: Mar 31, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Mar 17, 2021
Primary completion
Dec 21, 2021
Study completion Dec 21, 2021
Sponsor
- Lead sponsor
- Sylentis, S.A.Industry
- Sponsor type
- Industry
- First posted
- Mar 4, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Study of the safety, tolerability and pharmacokinetic profile of different doses of SYL1801 eye drops in healthy volunteers.
Conditions
- Safety, Tolerability and Pharmacokinetic Profile in Healthy Volunteers
- Choroidal Neovascularization
Interventions
SYL18001 sodium Low dose q.dDrug
1 drop in the randomized eye once daily
SYL18001 sodium Middle dose q.dDrug
1 drop in the randomized eye once daily
SYL18001 sodium High dose q.dDrug
1 drop in the randomized eye once daily
SYL18001 sodium High dose b.i.dDrug
1 drop in the randomized eye twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ocular tolerability at the site of administration (cornea and conjunctiva) after last instillation of the assigned dose level (1 day of treatment).Time frame: 72 hours after last instillation
- Ocular tolerability at the site of administration (cornea and conjunctiva) after last instillation of the assigned dose level (7 days of treatment).Time frame: 72 hours after last instillation
- Determination of the maximum Plasma Concentration [Cmax]Time frame: - 15 - 30 minutes, 1- 4 and 24 hours after last administration
- Determination of the Area Under the Curve of plasma concentrations until the last extraction time [AUT 0-t]Time frame: - 15 - 30 minutes, 1- 4 and 24 hours after last administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sylentis Clinical Trial Site
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.